Skip to main content

Piper Sees Blockbuster Revenue For Moderna Vaccine As Soon As Next Year

The analyst reiterates an Overweight rating on Moderna shares with a $57 price target after the FDA cleared the Phase 2 study to proceed.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.